Company profile
Claritas Pharmaceuticals, Inc.
OTC: CLAZF · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 23
v0.1 · 5/100 weight · pillars only
↑ return on equity, return on assets · ↓ workforce scale, market scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
$4.2M
Employees
3
as of 2026-08-30
Market cap
$3.7k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02020
Net income$4.2M$4.2M2020
Operating income-$3.3M-$3.3M2020
Total assets$10.4M$10.4M2020
Liabilities$8.9M$8.9M2020
Equity$1.5M$1.5M2020
Revenue trend
FY2013 – FY2020 · USD
FY13
FY14
FY15
FY16
FY17
FY18
FY19
FY20
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Claritas Pharmaceuticals, Inc.’s revenue?
Claritas Pharmaceuticals, Inc. booked $0 in FY2020 revenue — among the slowest-growing Healthcare companies we track, at a Infinity% net margin.
Peers · Healthcare
Innovation1 Biotech Inc.——Xeno Transplants Corporation——Tengion, Inc.——Sienna Biopharmaceuticals, Inc.——eFFECTOR Therapeutics, Inc.——Global Hemp Group Inc.——Neighbors
Marin →Key facts
CEORobert Farrell
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Rafael, CA
ExchangeOTC: CLAZF
Employees3
IPO date2016-04-12
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.